# Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B

> **NCT01228669** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 52 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A
- Haemophilia B
- Healthy

## Interventions

- **DRUG:** NNC 0172-0000-2021
- **DRUG:** NNC 0172-0000-2021
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01228669
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-25
- **Primary completion:** 2012-09-10
- **Final completion:** 2012-09-10
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01228669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01228669, "Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01228669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*